These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 11494042)
1. Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant. Sylvain V; Lafarge S; Bignon YJ Int J Oncol; 2001 Sep; 19(3):599-607. PubMed ID: 11494042 [TBL] [Abstract][Full Text] [Related]
2. Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Sylvain V; Lafarge S; Bignon YJ Int J Oncol; 2002 Apr; 20(4):845-53. PubMed ID: 11894135 [TBL] [Abstract][Full Text] [Related]
3. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544 [TBL] [Abstract][Full Text] [Related]
4. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345 [TBL] [Abstract][Full Text] [Related]
5. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. Aunoble B; Bernard-Gallon D; Bignon YJ Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099 [TBL] [Abstract][Full Text] [Related]
7. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Zhou C; Smith JL; Liu J Oncogene; 2003 Apr; 22(16):2396-404. PubMed ID: 12717416 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019 [TBL] [Abstract][Full Text] [Related]
9. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation. Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541 [TBL] [Abstract][Full Text] [Related]
10. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Somasundaram K; Zhang H; Zeng YX; Houvras Y; Peng Y; Zhang H; Wu GS; Licht JD; Weber BL; El-Deiry WS Nature; 1997 Sep; 389(6647):187-90. PubMed ID: 9296497 [TBL] [Abstract][Full Text] [Related]
11. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942 [TBL] [Abstract][Full Text] [Related]
12. [Cell cycle regulation after exposure to ionizing radiation]. Teyssier F; Bay JO; Dionet C; Verrelle P Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340 [TBL] [Abstract][Full Text] [Related]
14. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Sourvinos G; Spandidos DA Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786 [TBL] [Abstract][Full Text] [Related]
15. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832 [TBL] [Abstract][Full Text] [Related]
16. BRCA1 and p53 regulate critical prostate cancer pathways. De Luca P; Moiola CP; Zalazar F; Gardner K; Vazquez ES; De Siervi A Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):233-8. PubMed ID: 23670255 [TBL] [Abstract][Full Text] [Related]
17. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis. Reedy MB; Hang T; Gallion H; Arnold S; Smith SA Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136 [TBL] [Abstract][Full Text] [Related]
18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
19. Regulation by ionizing radiation of CDC2, cyclin A, cyclin B, thymidine kinase, topoisomerase IIalpha, and RAD51 expression in normal human diploid fibroblasts is dependent on p53/p21Waf1. de Toledo SM; Azzam EI; Keng P; Laffrenier S; Little JB Cell Growth Differ; 1998 Nov; 9(11):887-96. PubMed ID: 9831241 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. Fan S; Twu NF; Wang JA; Yuan RQ; Andres J; Goldberg ID; Rosen EM Int J Cancer; 1998 Aug; 77(4):600-9. PubMed ID: 9679765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]